Addressing injection-resistant wet-AMD
Millions suffer vision loss from PCV (polypoidal choroidal vasculopathy),
a sub-type of wet-AMD (advanced age-related macular degeneration).
Advanced age-related macular degeneration (wet-AMD) is the leading cause of vision loss in seniors globally.
CURRENT TREATMENT
Expensive, frequent, lifelong injections directly into the eye of anti-VEGF (anti-vascular endothelial growth factor) is the standard of care.
Half of patients treated with injections still suffer inadequate results.
INTRODUCING BETACURVE
SAVING VISION WITH PRECISION BETA RADIATION
SalutarisMD® [SMD] is a clinical stage medical device company. SMD's BetaCurve is a globally-patented, 510(k)-cleared device designed to treat various ophthalmic diseases with precision beta radiotherapy, including PCV.
The BetaCurve™ curves around the back of the eye to precisely deliver therapeutic beta radiation to the diseased area using a fiber optic light source for placement guidance.
The procedure is a outpatient, takes 10-minutes, and requires only one treatment. Utilizing a common technique, retina surgeons do not require additional methodological training.
PATENTED TECHNOLOGY
IP Portfolio Summary
Global patents protect
both the device and methods
for SMD’s precision delivery platform
Key patents granted in 50+ countries
BetaCurve is FDA 510k-cleared & ISO compliant
6 TRADEMARKS
13 DESIGN PATENTS
73 UTILITY PATENTS
CUTTING EDGE DESIGN FEATURES
SAFE TREATMENT
BetaCurve applies the well-established, therapeutic approach of low-dose beta radiation.
MINIMALLY INVASIVE
Our episcleral brachytherapy is an outpatient procedure using twilight anesthesia with minimal discomfort.
ACCURATE DOSIMETRY
The individualized treatment time ensures an accurate dose of beta radiotherapy.
PRECISION TARGETING
The retina surgeon targets the offending lesion with a precision beta radiotherapy delivery platform
A PROMISING ALTERNATIVE FOR THOSE PATIENTS WHO DO NOT RESPOND WELL TO ANTI-VEGF
CURRENT TREATMENT:
Anti-VEGF
-
Effective against classic wet-AMD, the type that primarily affects lightly pigmented individuals, especially Whites.
-
Improvement in vision is palliative due to underlying persistent disease activity
-
Requires a lifetime of injections (monthly for recalcitrant subtypes)
-
A temporary solution as patients often quit injections as early results fade or they develop drug resistance over time
-
Tremendous treatment burden due to needle anxiety, requisite frequent visits and scheduling logistics
NEW PROSPECTIVE TREATMENT:
BetaCurve
*
-
Future pivotal trial to show efficacy against PCV, the type that primarily affects pigmented individuals, especially Asians and Blacks
-
Designed to reduce or eliminate underlying disease
-
One-time treatment may reduce or eliminate injections altogether for all subtypes
-
Radiotherapy may prove to be durable and last a lifetime
-
Minimally-invasive, one-time procedure
MISSION
Saving vision for everyone
At SalutarisMD, our mission is to make treatment for AMD and other challenging retina diseases available to all, no matter the economic status or geographic location – an affordable, accessible, one-time treatment that can last a lifetime.
Frequent visits for anti-VEGF injection is not practical in many countries. One-time SMD precision radiotherapy can be made available everywhere.
